<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Blood doping,2000,2004,2004 Olympics,2005,Aerobic,Anemia,Autologous,B vitamins,Bay Area Laboratory Co-operative,Bicycle racing" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Blood doping - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Blood doping</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <p><b>Blood doping</b> is the practice of illicitly boosting the number of <a href="../../../r/e/d/Red_blood_cell.html" title="Red blood cell">red blood cells</a> (RBCs) in the circulation in order to enhance athletic performance. Because they carry <a href="../../../o/x/y/Oxygen.html" title="Oxygen">oxygen</a> from the <a href="../../../l/u/n/Lung.html" title="Lung">lungs</a> to the <a href="../../../m/u/s/Muscle.html" title="Muscle">muscles</a>, more RBCs in the blood can improve an athlete’s <a href="../../../a/e/r/Aerobic.html" title="Aerobic">aerobic</a> capacity and stamina.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Methods"><span class="tocnumber">1</span> <span class="toctext">Methods</span></a></li>
<li class="toclevel-1"><a href="#Testing_and_enforcement"><span class="tocnumber">2</span> <span class="toctext">Testing and enforcement</span></a>
<ul>
<li class="toclevel-2"><a href="#General_methods"><span class="tocnumber">2.1</span> <span class="toctext">General methods</span></a></li>
<li class="toclevel-2"><a href="#EPO"><span class="tocnumber">2.2</span> <span class="toctext">EPO</span></a></li>
<li class="toclevel-2"><a href="#Transfusions"><span class="tocnumber">2.3</span> <span class="toctext">Transfusions</span></a></li>
</ul>
</li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Methods" id="Methods"></a></p>
<h2><span class="editsection">[<a href="../../../b/l/o/Blood_doping.html" title="Edit section: Methods">edit</a>]</span> <span class="mw-headline">Methods</span></h2>
<p>The term blood doping originally meant literally <a href="../../../d/o/p/Doping_%28sport%29.html" title="Doping (sport)">doping</a> with blood, i.e. the <a href="../../../b/l/o/Blood_transfusion.html" title="Blood transfusion">transfusion</a> of RBCs. RBCs are uniquely suited to this process because they can be concentrated, frozen and later thawed with little loss of viability or activity. There are two possible types of transfusion: homologous and <a href="../../../a/u/t/Autologous.html" title="Autologous">autologous</a>. In a homologous transfusion, RBCs from a compatible donor are harvested, concentrated and then transfused into the athlete’s circulation prior to endurance competitions. In an autologous transfusion, the athlete harvests his own RBCs well in advance of competition and then re-introduces them before a critical event. For some time after the harvesting the athlete may be <a href="../../../a/n/e/Anemia.html" title="Anemia">anemic</a>.</p>
<p>Both types of transfusion can be dangerous because of the risk of infection and the potential toxicity of improperly stored blood. Homologous transfusions present the additional risks of communication of infectious diseases and the possibility of a transfusion reaction. From a logistical standpoint, either type of transfusion requires the athlete to surreptitiously transport frozen RBCs, thaw and re-infuse them in a non-clinical setting and then dispose of the medical paraphernalia.</p>
<p>In the late 1980s an advance in medicine led to an entirely new form of blood doping involving the hormone <a href="../../../e/r/y/Erythropoietin.html" title="Erythropoietin">erythropoietin</a> (EPO). EPO is a naturally-occurring <a href="../../../g/r/o/Growth_factor.html" title="Growth factor">growth factor</a> that stimulates the formation of RBCs. <a href="../../../r/e/c/Recombinant_DNA_technology_f95f.html" title="Recombinant DNA technology">Recombinant DNA technology</a> made it possible to produce EPO economically on a large scale and it was approved in US and Europe as a pharmaceutical product for the treatment of <a href="../../../a/n/e/Anemia.html" title="Anemia">anemia</a> resulting from <a href="../../../r/e/n/Renal_failure.html" title="Renal failure">renal failure</a> or <a href="../../../c/a/n/Cancer.html" title="Cancer">cancer</a> <a href="../../../c/h/e/Chemotherapy.html" title="Chemotherapy">chemotherapy</a>. Easily injected <a href="../../../s/u/b/Subcutis.html" title="Subcutis">under the skin</a>, pharmaceutical EPO can boost hematocrit for six weeks or longer. The use of EPO is now believed by many to be widespread in endurance sports such as professional <a href="../../../b/i/c/Bicycle_racing.html" title="Bicycle racing">bicycle racing</a>.</p>
<p>EPO is also not free of health hazards: excessive use of the hormone can cause <a href="../../../p/o/l/Polycythemia.html" title="Polycythemia">polycythemia</a>, a condition where the level of RBCs in the blood is abnormally high. This causes the blood to be more viscous than normal, a condition that strains the heart. Some elite athletes who died of heart failure—usually during sleep, when heart rate is naturally low—were found to have unnaturally high RBC concentrations in their blood.<sup class="noprint"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup></p>
<p><a name="Testing_and_enforcement" id="Testing_and_enforcement"></a></p>
<h2><span class="editsection">[<a href="../../../b/l/o/Blood_doping.html" title="Edit section: Testing and enforcement">edit</a>]</span> <span class="mw-headline">Testing and enforcement</span></h2>
<p><a name="General_methods" id="General_methods"></a></p>
<h3><span class="editsection">[<a href="../../../b/l/o/Blood_doping.html" title="Edit section: General methods">edit</a>]</span> <span class="mw-headline">General methods</span></h3>
<p>A time-honored approach to the detection of doping is the random and often repeated search of athletes’ homes and team facilities for evidence of a banned substance or practice. Professional cyclists customarily submit to random drug testing and searches of their homes as an obligation of team membership and participation in the <a href="../../../u/c/i/UCI_ProTour_2b13.html" title="UCI ProTour">UCI ProTour</a>. In <a href="../../../2/0/0/2004.html" title="2004">2004</a>, British cyclist <a href="../../../d/a/v/David_Millar_e680.html" title="David Millar">David Millar</a> was stripped of his world time-trial championship after pharmaceutical EPO was found in his possession. Because athletes sometimes <a href="../../../i/n/j/Injection_%28medicine%29.html" title="Injection (medicine)">inject</a> or <a href="../../../i/n/f/Infusion.html" title="Infusion">infuse</a> non-banned substances such as <a href="../../../b/_/v/B_vitamins.html" title="B vitamins">vitamin B</a> or <a href="../../../e/l/e/Electrolyte.html" title="Electrolyte">electrolytes</a>, the possession of <a href="../../../s/y/r/Syringe.html" title="Syringe">syringes</a> or other medical equipment is not necessarily evidence of doping.</p>
<p>It has also been possible to link athletes to blood doping entirely through documentary evidence, even if no banned substance has been found and no athlete has failed a doping test. The <a href="../../../b/a/y/Bay_Area_Laboratory_Co-operative_2df0.html" title="Bay Area Laboratory Co-operative">BALCO</a> and <a href="../../../o/p/e/Operaci%C3%B3n_Puerto_doping_case_7a18.html" title="Operación Puerto doping case">Operación Puerto</a> cases are recent examples.</p>
<p>A more modern approach, which has been applied to blood doping with mixed success, is to test the blood or urine of an athlete for evidence of a banned substance or practice. This approach requires a well-documented chain of custody of the sample and a test method that can be relied upon to be accurate and reproducible.</p>
<p>One strategy has been to regard any as evidence of blood doping. The <a href="../../../u/n/i/Union_Cycliste_Internationale_901f.html" title="Union Cycliste Internationale">Union Cycliste Internationale</a> (UCI), for example, imposes a 15-day suspension from racing on any male athlete found to have a hematocrit above 50% and a hemoglobin concentration above 17 g/dL. A few athletes have normally high RBC concentrations, especially if they have <a href="../../../p/o/l/Polycythemia.html" title="Polycythemia">polycythemia</a>, which they must demonstrate through a series of consistently high hematocrit and hemoglobin results over an extended period of time. (<a href="../../../h/e/m/Hematocrit.html" title="Hematocrit">Hematocrit</a> (HCT) is the fraction of blood cells by volume that are RBCs. A normal HCT is 41-50% in adult men and 36-44% in adult women <a href="http://www.nlm.nih.gov/medlineplus/ency/article/003646.htm" class="external autonumber" title="http://www.nlm.nih.gov/medlineplus/ency/article/003646.htm" rel="nofollow">[1]</a>. <a href="../../../h/e/m/Hemoglobin.html" title="Hemoglobin">Hemoglobin</a> (Hb) is the <a href="../../../i/r/o/Iron.html" title="Iron">iron</a>-containing <a href="../../../p/r/o/Protein.html" title="Protein">protein</a> that binds <a href="../../../o/x/y/Oxygen.html" title="Oxygen">oxygen</a> in RBCs. Normal Hb levels are 14-17 <a href="../../../g/r/a/Gram.html" title="Gram">grams</a> per <a href="../../../l/i/t/Litre.html" title="Litre">deciliter</a> (G/dL) of blood in men and 12-15 g/dL in women.)</p>
<p>A more recent and more sophisticated method of analysis, which has not yet reached the level of an official standard, is to compare the levels of mature and immature RBCs in an athlete's circulation. If a high number of mature RBCs is not accompanied by a high number of immature RBCs--called <a href="../../../r/e/t/Reticulocyte.html" title="Reticulocyte">reticulocytes</a>--it suggests that the mature RBCs were artificially introduced by transfusion. EPO use can also lead to a similar RBC profile because a preponderance of mature RBCs tends to suppress the formation of reticulocytes. A measure known as the "stimulation index" or "off-score" has been proposed based on an equation involving hemoglobin and reticulocyte concentrations. A normal score is 85-95 and scores over 133 are considered evidence of doping. (The stimulation index is defined as Hb (g/L) minus sixty times the square root of the reticulocyte amount (%).)</p>
<p><a name="EPO" id="EPO"></a></p>
<h3><span class="editsection">[<a href="../../../b/l/o/Blood_doping.html" title="Edit section: EPO">edit</a>]</span> <span class="mw-headline">EPO</span></h3>
<p>Some success has also been realized in applying a specific test to detect EPO use. In <a href="../../../2/0/0/2000.html" title="2000">2000</a> a test developed by scientists at the <a href="../../../f/r/a/France.html" title="France">French</a> national anti-doping laboratory (<a href="../../../l/n/d/LNDD_32f6.html" title="LNDD">LNDD</a>) and endorsed by the <a href="../../../w/o/r/World_Anti-Doping_Agency_42d6.html" title="World Anti-Doping Agency">World Anti-Doping Agency</a> (WADA) was introduced to detect pharmaceutical EPO by distinguishing it from the nearly identical natural hormone normally present in an athlete’s <a href="../../../u/r/i/Urine.html" title="Urine">urine</a>. The test method relies on scientific techniques known as <a href="../../../g/e/l/Gel_electrophoresis.html" title="Gel electrophoresis">gel electrophoresis</a> and <a href="../../../i/s/o/Isoelectric_focusing.html" title="Isoelectric focusing">isoelectric focusing</a>. Although the test has been widely applied, especially among cyclists and <a href="../../../t/r/i/Triathlete.html" title="Triathlete">triathletes</a>, it is highly controversial and its accuracy has been called into question. The principal criticism has been the ability of the test to distinguish pharmaceutical EPO from other proteins that may normally be present in the urine of an athlete after strenuous exercise.</p>
<p>The validity of a doping conviction based on the EPO test method was first challenged successfully by Belgian triathelete Rutger Beke. Beke was suspended from competition for 18 months in March <a href="../../../2/0/0/2005.html" title="2005">2005</a> by the Flemish Disciplinary Commission after a positive urine test for EPO in September <a href="../../../2/0/0/2004.html" title="2004">2004</a>. In August <a href="../../../2/0/0/2005.html" title="2005">2005</a> the Commission reversed its decision and exonerated him based on scientific and medical information presented by Beke. He asserted that his sample had become degraded as a result of bacterial contamination and that the substance identified by the laboratory as pharmaceutical EPO was, in fact, an unrelated protein indistinguishable from pharmaceutical EPO in the test method. He claimed, therefore, that the test had produced a <a href="../../../f/a/l/False_positive.html" title="False positive">false positive</a> result in his case.</p>
<p><a name="Transfusions" id="Transfusions"></a></p>
<h3><span class="editsection">[<a href="../../../b/l/o/Blood_doping.html" title="Edit section: Transfusions">edit</a>]</span> <span class="mw-headline">Transfusions</span></h3>
<p>In the case of detecting blood transfusions, a test for detecting homologous blood transfusions (from a donor to a doping athlete) has been in use since <a href="../../../2/0/0/2000.html" title="2000">2000</a>. The test method is based on a technique known as <a href="../../../f/l/u/Fluorescent-activated_cell_sorting.html" title="Fluorescent-activated cell sorting">fluorescent-activated cell sorting</a>. By examining markers on the surface of blood cells, the method can determine whether blood from more than one person is present in an athlete’s circulation.</p>
<p>The American cyclist <a href="../../../t/y/l/Tyler_Hamilton_ce65.html" title="Tyler Hamilton">Tyler Hamilton</a> failed this test during the <a href="../../../2/0/0/2004_Olympics_3a7b.html" title="2004 Olympics">2004 Olympics</a> but was allowed to keep his gold medal because the processing of his sample precluded conducting a second, confirmatory test. He appealed a second positive test for homologous transfusion from the <a href="../../../2/0/0/2004.html" title="2004">2004</a> <a href="../../../v/u/e/Vuelta_a_Espa%C3%B1a_9ef0.html" title="Vuelta a España">Vuelta a España</a> to the International <a href="../../../c/o/u/Court_of_Arbitration_for_Sport_553f.html" title="Court of Arbitration for Sport">Court of Arbitration for Sport</a> but his appeal was denied.</p>
<p>At present there is no accepted way of detecting autologous transfusions (using the athlete’s own RBCs) but research is in progress and the <a href="../../../w/o/r/World_Anti-Doping_Agency_42d6.html" title="World Anti-Doping Agency">World Anti-Doping Agency</a> (WADA) has promised that a test will eventually be introduced. The test method and its introduction date are to be kept secret in order to avoid tipping off doping athletes.</p>

<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../b/l/o/Blood_doping.html">http://en.wikipedia.org../../../b/l/o/Blood_doping.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../a/r/t/Category%7EArticles_with_unsourced_statements_since_February_2007_f7dc.html" title="Category:Articles with unsourced statements since February 2007">Articles with unsourced statements since February 2007</a></span> | <span dir='ltr'><a href="../../../a/l/l/Category%7EAll_articles_with_unsourced_statements_2f67.html" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></span> | <span dir='ltr'><a href="../../../d/r/u/Category%7EDrugs_in_sport_4f11.html" title="Category:Drugs in sport">Drugs in sport</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../b/l/o/Blood_doping.html">Article</a></li><li id="ca-talk"
	       class="new"	       ><a href="../../../b/l/o/Talk%7EBlood_doping_d316.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Blood_doping">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../ar/%D8%AA/%D9%86/%D8%B4/%D8%AA%D9%86%D8%B4%D9%8A%D8%B7_%D8%A7%D9%84%D8%AF%D9%85.html">العربية</a>
	      </li>
	      	      <li>
	      <a href="../../../../da/b/l/o/Bloddoping.html">Dansk</a>
	      </li>
	      	      <li>
	      <a href="../../../../de/b/l/u/Blutdoping.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../nl/b/l/o/Bloeddoping.html">Nederlands</a>
	      </li>
	      	      <li>
	      <a href="../../../../no/b/l/o/Bloddoping.html">‪Norsk (bokmål)‬</a>
	      </li>
	      	      <li>
	      <a href="../../../../sv/b/l/o/Bloddopning.html">Svenska</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 21:44, 22 March 2007 by Anonymous user(s) of Wikipedia. Based on work by Wikipedia user(s) <a href="../../../u/r/z/User%7EUrzadek_86f8.html" title="User:Urzadek">Urzadek</a>, <a href="../../../j/a/x/User%7EJaxsonjo_9a1b.html" title="User:Jaxsonjo">Jaxsonjo</a>, <a href="../../../r/w/y/User%7ERWyn_1fcb.html" title="User:RWyn">RWyn</a>, <a href="../../../s/m/a/User%7ESmackBot_cc7a.html" title="User:SmackBot">SmackBot</a>, <a href="../../../t/s/u/User%7ETsujigiri_f5a1.html" title="User:Tsujigiri">Tsujigiri</a>, <a href="../../../r/a/v/User%7ERaven4x4x_5184.html" title="User:Raven4x4x">Raven4x4x</a>, <a href="../../../a/n/t/User%7EAntiVandalBot_aa84.html" title="User:AntiVandalBot">AntiVandalBot</a>, <a href="../../../b/o/s/User%7EBoston2austin_1170.html" title="User:Boston2austin">Boston2austin</a>, <a href="../../../s/t/b/User%7ESTBot_bbca.html" title="User:STBot">STBot</a>, <a href="../../../m/o/h/User%7EMohammed_Khalil_ade5.html" title="User:Mohammed Khalil">Mohammed Khalil</a>, <a href="../../../d/a/v/User%7EDavid_D._77aa.html" title="User:David D.">David D.</a>, <a href="../../../h/a/p/User%7EHappily_ever_after_060b.html" title="User:Happily ever after">Happily ever after</a>, <a href="../../../n/a/t/User%7ENatalinasmpf_1971.html" title="User:Natalinasmpf">Natalinasmpf</a>, <a href="../../../f/u/n/User%7EFunnyMan3595_39fb.html" title="User:FunnyMan3595">FunnyMan3595</a>, BitQuirky, <a href="../../../h/e/d/User%7EHede2000_86f6.html" title="User:Hede2000">Hede2000</a>, <a href="../../../w/e/g/User%7EWeggeBot_7120.html" title="User:WeggeBot">WeggeBot</a>, <a href="../../../c/y/g/User%7ECygnusPius_73f1.html" title="User:CygnusPius">CygnusPius</a>, <a href="../../../e/v/e/User%7EEveryking_5c9e.html" title="User:Everyking">Everyking</a>, <a href="../../../s/z/q/User%7ESzquirrel_f18c.html" title="User:Szquirrel">Szquirrel</a>, <a href="../../../s/p/a/User%7ESpaully_efd5.html" title="User:Spaully">Spaully</a>, <a href="../../../m/r/t/User%7EMrTroy_5e9d.html" title="User:MrTroy">MrTroy</a>, <a href="../../../s/h/a/User%7EShaggorama_a518.html" title="User:Shaggorama">Shaggorama</a>, <a href="../../../z/e/_/User%7EZe_miguel_0384.html" title="User:Ze miguel">Ze miguel</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../a/k/a/User%7EAkamad_92a5.html" title="User:Akamad">Akamad</a>, <a href="../../../l/u/p/User%7ELupin_68a5.html" title="User:Lupin">Lupin</a>, <a href="../../../s/a/n/User%7ESango123_0773.html" title="User:Sango123">Sango123</a>, <a href="../../../j/a/c/User%7EJacqui_M_e8a5.html" title="User:Jacqui M">Jacqui M</a> and <a href="../../../f/i/r/User%7EFire_Star_28a1.html" title="User:Fire Star">Fire Star</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
